About Us - Momentum Biotechnologies

Momentum Biotechnologies is a drug discovery partner offering specialized, cutting-edge mass spectrometry technologies to biopharmaceutical clients across the globe.

Our expert scientific team is committed to providing superior CRO services to drive innovations in drug discovery and development, combining deep expertise with a passion for science and creative problem-solving. Our dedication to providing exceptional service with rapid turnaround times enables our clients to accelerate their research process without compromising data quality or experimental rigor. Our research labs are located outside of Boston in Billerica, Massachusetts, and outside of Munich in Freising, Germany.

Our Leadership Team

Can Ozbal, Ph.D.

Founder & Chief Executive Officer

William LaMarr, Ph.D.

Chief Scientific Officer

Arrin Katz, M.S.

Chief Operating Officer

Daniel Brooks, M.B.A.

Chief Financial Officer

Daniel Cohen

Chief Commercial Officer

Hannes Hahne, Ph.D.

President, OmicScouts

Kathrin Grunder-Culemann, Ph.D.

Chief Operating Officer, OmicScouts

Wendy Picariello

VP, Operations

Peter Rye, Ph.D.

VP, Application Development

Donald Green, M.S.

VP, Software Engineering

Scientific Advisory Board

Kevin Bateman, PhD

Former Scientific Associate Vice President

Merck Research Laboratories

Ying Lu, PhD

Professor

Harvard Medical School

Bernhard Kuster, PhD

Professor

Technical University of Munich

Mathias Wilhelm, PhD

Professor

Technical University of Munich

History of Momentum Biotechnologies

Our core team has a proud history of working together for over 20 years to support scientific discovery.

2000

Initial funding by Pfizer and Amgen of MIT technology

2004

RapidFire services commercialized

2006

RapidFire instrument commercialized

2009

Spun off from BioTrove as BIOCIUS Life Sciences

2011

Acquired by Agilent Technologies

2015

PureHoney Technologies established as a CRO to provide mass spec-based screening services

2023

PureHoney rebrands to Momentum Biotechnologies and invests ~$10M to increase service offerings

2025

Acquisition of OmicScouts expands proteomic services and establishes Momentum’s global presence

Partners in Technology

AXXAM

Additional chemical libraries
Orthogonal assays

Proteros

Protein expression and purification
Additional chemical libraries

Beantown Biotech

Cell culture assays and sample prep
Orthogonal assays

Cube Biotech

Membrane protein expression and purification
NativeMP™platform

Careers

At Momentum, we strive to enable new frontiers of pharmaceutical innovation through teamwork-driven collaborations with clients.

Momentum Biotechnologies is dedicated to accelerating drug discovery and development by providing innovative solutions that solve our clients’ biggest challenges. Our success is fueled by the passion and commitment of our team, including our scientists, administrators, and other employees. Our company culture prioritizes teamwork, integrity, and bias-to-action, enabling us to readily overcome roadblocks and develop creative solutions for our clients. We operate lab facilities in Billerica, Massachusetts, and Freising, Germany. Key benefits include:

The opportunity to drive therapeutic innovation and impact the future of scientific discovery
A friendly, open-minded, and collaborative work environment with a focus on positive reinforcement and job satisfaction
A strong commitment to professional development and growth across all levels of our organization

View Current Openings

Latest News

May 28, 2025

•SAB

Billerica, MA and Freising, Germany

Momentum Biotechnologies Expands Scientific Advisory Board with Two New Additions

Momentum Biotechnologies ("Momentum"), a contract research organization specializing in mass spectrometry-based drug discovery and proteomics, announced today...

March 4, 2025

•Acquisition

Billerica, MA and Freising, Germany

Momentum Biotechnologies Announces Acquisition of OmicScouts

https://vimeo.com/1071860408 Momentum Biotechnologies (“Momentum”), a contract research organization (“CRO”) specializing in mass spectrometry-based drug...

August 8, 2024

•Partnerships

Billerica, MA and Monheim, Germany

Momentum Biotechnologies and Cube Biotech Announce Strategic Partnership

Momentum Biotechnologies, an innovative contract research organization ("CRO") for mass spectrometry-based drug discovery, and Cube Biotech, a leader in...

View all News